Since becoming Biogen Idec's CEO three years ago, George Scangos has helped quadruple the company's market value. Now, he is under pressure to successfully guide the long-anticipated launch of its MS drug Tecfidera.

By Zacks Investment Research: Although markets have been shaky of late, a few sectors have managed to hold up surprisingly well. In particular, there has been great strength in the healthcare space, as this segment is currently leading the market fro

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates.

Biogen IDEC Inc (BIIB) June 12, 2013 9:00 am ET Executives William D. Young - Independent Chairman, Member of Corporate Governance Committee and Member of Science & Technology Committee Susan H. Alexander - Executive Vice President, Secretary and Gen

Check out Jim Cramer's latest trading recommendations on"Action Alerts Plus".NEW YORK (TheStreet) -- Here's what Jim Cramer had to say on CNBC's "Squawk On The Street" Wednesday.Biogen Idec investors are worried about drug protection in Europe but Cr

Analysts at Citigroup downgraded Biogen Idec (NASDAQ: BIIB) from “buy” to “neutral.” The target price for Biogen Idec has been raised from $235 to $236. Biogen Idec's shares closed at $223.03 yesterday.

By Brian L. Wilson:Yesterday, Biogen Idec (NASDAQ: BIIB) was the worst performer amongst the larger pharmaceutical companies after Cowen analyst Eric Schmidt pointed that the IMS prescription sales data for new prescriptions (NRx) of the company's re

ByAbba's Aces:Since the beginning of the year all biotech and pharma companies have been making excellent gains, however, the biotech companies such as Celgene (CELG), Gilead (GILD), Biogen Idec (BIIB), and Regeneron (REGN) have been faltering of lat

In a report on Biogen (NASDAQ: BIIB) published Tuesday, Cowen Group analyst Eric Schmidt suggested weekly prescription data report from IMS Health might contain some double-counting on Tecifera prescriptions.Schmidt believes the number of new patient

Investors eyeing a purchase of Biogen Idec Inc (NASD: BIIB) shares, but tentative about paying the going market price of $225.98/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting pu

May 30 (Reuters) - Biogen Idec Inc expects a delay in the European launch of its multiple sclerosis drug Tecfidera as the drugmaker works to secure exclusive data that could potentially protect its treatment from generic competition for a longer peri

May 30 (Reuters) - Biogen Idec Inc expects a delayin the European launch of its multiple sclerosis drug Tecfideraas the drugmaker works to secure exclusive data that couldpotentially protect its...

Among biotech and emerging pharmaceutical companies, Regeneron Pharmaceuticals (NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw he most significant rise in short interest between the April 30 and May 15 settlement dates.The number of sha

Biogen submits Plegridy for FDA approval.

Today BiogenIdec (NASDAQ: BIIB) announced it has submitted a Biologics LicenseApplication (BLA) to the U.S.

Traders in shares of Biogen (NASDAQ: BIIB) are responding to an earlier research note from Leerink Swann analyst Marko Kozul.

Biogen's MS drug is off to a hot start, and its new hemophilia drugs are under FDA review.

(Corrects paragraph 12 to show Biogen has stake in new drug)

(Corrects paragraph 12 to show Biogen has stake in new drug)

(Corrects paragraph 12 to show Biogen has stake in new drug)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter.

Editor's Note: This article was originally published on Real Money at 12:52 p.m. EDT on May 10. To see Jim Cramer's latest commentary as it's published, sign up for a free trial of Real Money. NEW YORK (Real Money) -- So, Celgene, Regeneron , Biogen

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive"Mad Money" Stock Screener.NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the stocks callers offered up during the "Mad Money Lightning Round" Thursda

Cramer also likes SunTrust and Crosstex Energy but isn't impressed by Mondelez International. Click to view a price quote on STI. Click to research the Banking industry.    

Isis Pharmaceuticals (NASDAQ: ISIS) announced today that is has earned a $3.5 million milestone payment from Biogen Idec associated with the dosing of the first patient in a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA).

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Biogen Idec Inc (NASD: BIIB) has taken over the #169 spot from United Parcel Service Inc (NYSE: UPS), according to ETF Channel. Below is

NEW YORK (TheStreet) -- CHANGE IN RATINGSAmgenwas upgraded at Goldman Sachs to buy from neutral. $130 price target. Company was also added to the Conviction Buy List, as the company has multiple potential catalysts, Goldman said. Biogen Idecwas downg

By William Meyers: Biogen Idec (BIIB) is now off its 52-week high of $226.18 (reachedearlier today), but up from a 52-week low of $126.39 (as of June 4, 2012).At $218.84 it has risen 73% off the low. I began following BIIBin the first quarter of 2006

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April.The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ:

Biogen Idec (BIIB)Q1 2013 Earnings CallApril 25, 20138:00 am ETExecutivesClaudine ProwseGeorge A. Scangos - Chief Executive Officer and DirectorTony Kingsley - Executive Vice President of Global Commercial OperationsDouglas Edward Williams - Executiv

April 25 (Reuters) - Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple scl

Clean earnings reports from Biogen and Alexion reported so far, Celgene comes in a bit light. Click to view a price quote on AMGN. Click to research the Drugs industry.    

April 25 (Reuters) - Biogen Idec Inc : * Says believes tecfidera will become leading oral drug in ms market

April 25 (Reuters) - Biogen Idec Inc reportedhigher-than-expected first quarter profit on Thursday, helped bylow taxes and sales growth of its injectable multiple sclerosistreatments, and the U.S. biotechnology company raised itsfull-year forecast.

April 25 (Reuters) - Biogen Idec Inc reported higher-than-expected first quarter profit on Thursday, helped by low taxes and sales growth of its injectable multiple sclerosis treatments, and the U.S. biotechnology company raised its full-year forecas

BOSTON (TheStreet) -- Waiting for trading to kick into higher gear Thursday to see if the jagged nerves of biotech investors settle following a slew of important first-quarter earnings reports. Biogen Idecand Alexion Pharmaceuticalslook clean and bot

April 25 (Reuters) - Biogen Idec Inc reported stronger-than-expected quarterly earnings, helped by unusually low taxes and sales growth of its treatments for multiple sclerosis.

Analysts expect higher profit for Biogen Idec (BIIB) when the company reports its first quarter results on Thursday, April 25, 2013. The consensus estimate is calling for profit of $1.57 a share, reflecting a rise from $1.39 per share a year ago.

First week prescriptions for Biogen's Tecfidera are squashing the competition. Click to view a price quote on BIIB. Click to research the Drugs industry.    

CAMBRIDGE, Mass. (TheStreet) -- Biogen Idec'smultiple sclerosis pill Tecfidera is off to a blazing commercial launch.Check out the green, nearly vertical line, in the graph above. It represents one week of Tecfidera scripts, per IMS Health. As ISI Gr

Today Biogen Idec (NASDAQ: BIIB) announced that results from the daclizumabhigh-yield process (DAC HYP) SELECT clinical trial have been published as anonline article in The Lancet.

DUBLIN, April 2 (Reuters) - Irish drugmaker Elan closed the sale of its 50 percent stake in multiple sclerosis (MS) drug Tysabri on Tuesday, clearing the way for it to return cash to investors, spend...

DUBLIN, April 2 (Reuters) - Irish drugmaker Elan closed the sale of its 50 percent stake in multiple sclerosis (MS) drug Tysabri on Tuesday, clearing the way for it to return cash to investors, spend on acquisitions and stave off an approach for the

DUBLIN, April 2 (Reuters) - Irish drugmaker Elan closed the sale of its 50 percent stake in multiple sclerosis (MS) drug Tysabri on Tuesday, clearing the way for it to return cash to investors, spend on acquisitions and stave off an approach for the

DUBLIN, April 2 (Reuters) - Irish drugmaker Elan closed the sale of its 50 percent stake in multiple sclerosis (MS) drug Tysabri on Tuesday, clearing the way for it to return cash to investors, spend on acquisitions and stave off an approach for the